Table 1.
Demographic and clinical characteristics of RA patients, according to presence of anti-MCV IgG antibodies
| Assay | Early RA (n = 33) | Established RA (n = 68) | ||
|---|---|---|---|---|
| MCV+ (n = 27) | MCV− (n = 6) | MCV+ (n = 60) | MCV− (n = 8) | |
| F, n (%) | 19 (70.4) | 5 (83.3) | 52 (86.7) | 6 (75.0) |
| Age in years, m (IQR) | 50 (41–59) | 43 (32–48) | 52 (43–51) | 57 (48–71) |
| Smoker, n (%) | 7 (25.9) | 1 (16.7) | 11 (18.3) | 1 (12.5) |
| Disease duration in years, m (IQR) | 1.0 (0.5–1.0) | 0.9 (0.8–1.0) | 6.0 (3.0–11.0) | 11.0 (5.0–16.2) |
| DAS28, m (IQR) | 5.3 (4.2–6.3) | 3.3 (3.0–4.9) | 5.1 (3.8–5.9) | 5.0 (4.5–5.7) |
| Remission: DAS28 ≤ 2.6; n (%) | 1 (3.7) | 0 | 6 (10.0) | 0 |
| Low: DAS28 > 2.6 and ≤ 3.2, n (%) | 2 (7.4) | 3 (50.0) | 7 (11.7) | 5 (62.5) |
| Moderate: DAS28 > 3.2 and ≤ 5.1, n(%) | 9 (33.3) | 1 (16.7) | 19 (31.7) | 5 (62.5) |
| High: DAS28 > 5.1, n (%) | 15 (55.6) | 2 (33.4) | 28 (46.7) | 3 (37.5) |
| HAQ, m (IQR) | 0.60 (0.44–0.81) | 0.28 (0.25–0.24) | 0.75 (0.25–1.37) | 1.06 (0.81–1.41) |
| ESR, m (IQR) | 44.0 (25.5–64.5) | 16.0 (13.5–21.5) | 29.0 (16.0–54.2) | 26.0 (16.3–62.8) |
| CRP positivity, n (%) | 21 (77.8) | 1 (16.7) | 36 (60.0) | 2 (25.0) |
RA rheumatoid arthritis, n number of patients, DAS28 disease activity score, ESR erythrocyte sedimentation rate, CRP C-reactive protein, HAQ Health Assessment Questionnaire Index, m median, n number of patients, IQR interquartile range
* Significant differences between anti-MCV IgG positive and negative groups on median (p < 0.05)